Castellazzi Massimiliano, Tamborino Carmine, Fainardi Enrico, Manfrinato Maria C, Granieri Enrico, Dallocchio Franco, Bellini Tiziana
Department of Medical and Surgical Sciences of the Communication and Behaviour, Section of Neurology, University of Ferrara, Ferrara I-44100, Italy.
Clin Biochem. 2007 Nov;40(16-17):1272-6. doi: 10.1016/j.clinbiochem.2007.08.011. Epub 2007 Aug 24.
To identify the best procedure for preanalytical blood collection in the determination of matrix metalloproteinase (MMP)-2 and -9 by testing the effects of anticoagulants on their activity.
Active forms of both gelatinases were measured by specific activity assay systems in serum, plasma EDTA, plasma-heparin and plasma-citrate obtained from 20 healthy volunteers, as well as in a pooled serum sample before and after anticoagulant treatment.
: Active MMP-2 and MMP-9 mean concentrations were similar in serum and in plasma-citrate, higher in plasma EDTA than in serum, in plasma-heparin and in plasma-citrate, and lower in plasma-heparin than in serum and plasma-citrate. A similar trend was observed in untreated and treated pooled serum samples.
Our results indicate that MMP-2 and MMP-9 in their active forms are not released by platelets during blood clotting, whereas the use of calcium chelating anticoagulants can profoundly alter the activity of endogenous gelatinases. This suggests that the determination of active forms of MMP-2 and MMP-9 in serum samples represents a suitable procedure.
通过检测抗凝剂对基质金属蛋白酶（MMP）-2和-9活性的影响，确定在测定这两种酶时分析前血液采集的最佳程序。
采用特定活性测定系统，对20名健康志愿者的血清、乙二胺四乙酸（EDTA）血浆、肝素血浆和柠檬酸盐血浆中的两种明胶酶的活性形式进行测定，并对抗凝剂处理前后的混合血清样本进行检测。
血清和柠檬酸盐血浆中活性MMP-2和MMP-9的平均浓度相似，EDTA血浆中的浓度高于血清、肝素血浆和柠檬酸盐血浆，肝素血浆中的浓度低于血清和柠檬酸盐血浆。在未经处理和处理过的混合血清样本中也观察到类似趋势。
我们的结果表明，活性形式的MMP-2和MMP-9在血液凝固过程中不会由血小板释放，而使用钙螯合抗凝剂会深刻改变内源性明胶酶的活性。这表明测定血清样本中活性形式的MMP-2和MMP-9是一种合适的程序。
